Biocept Announces $11.6 Million in Expected Gross Proceeds from Recently Expired Rights Offering
Each right entitled the holder to purchase one unit, at a subscription price of
This press release does not constitute an offer to sell or the solicitation of an offer to buy the subscription rights or the underlying securities, nor will there be any sale of the subscription rights or the underlying securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
Forward-Looking Statements Disclaimer Statement
This news release contains forward-looking statements that are based upon current expectations or beliefs, as well as a number of assumptions about future events. Although we believe that the expectations reflected in the forward-looking statements and the assumptions upon which they are based are reasonable, we can give no assurance that such expectations and assumptions will prove to be correct. Forward-looking statements are generally identifiable by the use of words like "may," "will," "should," "could," "expect," "anticipate," "estimate," "believe," "intend" or "project," or the negative of these words or other variations on these words or comparable terminology. To the extent that statements in this news release are not strictly historical, including, without limitation, statements as to our ability to improve the outcomes of cancer patients, the utility and cost effectiveness of our tests, our ability to further validate our liquid biopsy technology, and our ability to expand our relationships with managed care organizations and integrated healthcare delivery networks, such statements are forward-looking, and are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The reader is cautioned not to put undue reliance on these forward-looking statements, as these statements are subject to numerous risk factors as set forth in our
View original content with multimedia:http://www.prnewswire.com/news-releases/biocept-announces-11-6-million-in-expected-gross-proceeds-from-recently-expired-rights-offering-300694556.html
Investor Contact: LHA Investor Relations, Jody Cain, Jcain@lhai.com, 310-691-7100 or Media Contact: Trevelino/Keller, Colleen Murphy, email@example.com, 404-214-0722, Ext. 109